Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Myokardia Inc (MYOK)

Myokardia Inc (MYOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Myokardia Inc 1000 SIERRA POINT PARKWAY BRISBANE CA 94005 USA

www.myokardia.com P: 650-741-0900

Description:

MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy, DCM-1, treats heritable dilated cardiomyopathy by restoring normal contractility in the diseased DCM heart, HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients and LUS-1, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart, which are in different clinical trial. MyoKardia, Inc. is headquartered in San Francisco, California.

Key Statistics

Overview:

Market Capitalization, $K 11,992,876
Shares Outstanding, K 53,323
Annual Sales, $ 0 K
Annual Net Income, $ -276,210 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -84,740 K
60-Month Beta 1.84
% of Insider Shareholders 5.20%
% of Institutional Shareholders 95.16%
Float, K 50,550
% Float 94.80%

Growth:

1-Year Return 309.30%
3-Year Return 538.04%
5-Year Return 1,713.79%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 11/09/20
Earnings Per Share ttm -5.64
EPS Growth vs. Prev Qtr -25.98%
EPS Growth vs. Prev Year -19.40%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

MYOK Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -44.14%
Return-on-Assets % -37.78%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 14.11
Book Value/Share 15.94
Interest Coverage -24.77
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar